CRISPR Therapeutics’ Post

Hear more about Artisan's STAR-CRISPR system with Scientist Steven Loo-Yong-Kee in this STEMCELL Technologies webinar.

One week to go before our next CGT webinar - will you be joining us? Preclinical in vitro and in vivo evaluations and CMC characterization of cell and gene therapy (CGT) products contribute significantly to characterization of the product benefit versus risk profile throughout development. The field is currently expanding rapidly, with many candidate therapies advancing into clinical testing and many more progressing through preclinical pipelines. As the number of early-stage candidate products continues to increase, so does the need to define effective preclinical and CMC development strategies that support successful IND submission and clinical translation. This webinar will discuss the considerations to be taken into account when designing your gene therapy preclinical and CMC development strategies. We will share our experience to help build successful strategies that carefully balance time and cost whilst always ensuring quality to meet regulatory needs. Registration link below ⬇

With ongoing financial turmoil, would you like to be budget savvy while keeping the scientific impact of your IND enabling studies and CMC intact? As a part of this forum, we will discuss a few tips about how to design your pre-clinical studies and CMC strategies while working with a budget in mind. Join us. #cmc #cellandgenetherapy #aav

We're hyped to be going to The Bioprocessing Summit! Cruise by booth #405 or check out our talks to learn how our solutions can help you navigate bottlenecks in your biologics or gene therapy workflow!  #CHIBioprocessingSummit

Take a look at this article, co-authored by Zhe Liu, PhD, Labcorp staff scientist, which focuses on development of a preclinical anti-AAV antibody assay to enable screening for pre-existing AAV immunity. Discover how this assay can help gene therapy developers identify potential low-responding individuals, increase the likelihood of successful transduction and maximize the utility of the preclinical investigations. Read the full article: http://spr.ly/6040pXp5E #GeneTherapy #AAV #CellandGeneTherapy

The supply chain for cell and gene therapies is complex and requires next-level precision and oversight. Learn more about what you can do to bridge the gap between manufacturing and delivery of the finished therapy to the patient. https://ow.ly/3s7650P9xcG https://bit.ly/46LMUgr

We are very pleased to announce that our CEO, Eric Halioua will be on stage today in a panel at the Cell Therapy Manufacturing & Gene Therapy Congress organized by Informa in Dublin, Ireland. At 11:30 Eric, accompanied by Imen Mestiri, Thibault Jonckheere, and George Frodsham, will address Partnership Challenges in Cell & Gene Therapy as the market conditions change. What will be discussed? - Exploring the impacts of market conditions on CGT partnerships. - Understanding the evolving landscape of collaboration between small innovators and large biotechs. - Evaluating current partnership strategies and how they can be improved. https://lnkd.in/eeWBzXk

Data from the CombiGene Spark Therapeutics. Epilepsy collaboration project was presented at the Annual Meeting of ASCGT (American Society for Gene & Cell Therapy), in Baltimore. The abstract was selected for an oral session and was presented by PhD Barbara Terzic from Spark Therapeutics. Abstract 307: Establishment of Gene Therapy Drug Development Assays Confirms Antiepileptic Activity of an AAV Encoding Neuropeptide Y (NPY) and Y2 Receptor (Y2R). https://lnkd.in/dNMjkqwc